MUMBAI, India, Aug. 4, 2023 /PRNewswire/ — Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635), today announced its consolidated results for the first quarter (Q1) ended June 30, 2023.
Highlights for the first quarter of fiscal year 2024
Nandini Piramal, Chairman of Piramal Pharma Limited, explained: “We had a positive start to the new fiscal year with healthy revenue growth and improvement in our EBITDA margins. Our CDMO business is also seeing a continued flow of orders, especially for our differentiated offerings and work related to innovation.Our Inhalation Anesthesia portfolio is seeing healthy demand and our Consumer Healthcare business in India is generating good growth driven by powerful brands.We continue to maintain our best track record of quality in its class and we are also taking multiple initiatives in the area of ESG to grow our business responsibly.
Historically, our second half has been better than the first half, both in terms of revenue and profitability. We are working to build on our strong start to the fiscal year and continue this momentum to deliver a healthy year-on-year performance for the remainder of the year. We believe in the growth potential of our business and accordingly we are executing on our strategic priorities to create shareholder value. Our promoter and promoter group have agreed to subscribe for up to 100% of the equity shares offered in our rights issue, thereby reaffirming their confidence in the underlying strengths of our business.”
Fiscal Year 2024 First Quarter Earnings Conference Call
Piramal Pharma Limited will host an investor/analyst conference call on August 4, 2023 at 10:00 AM. m. (IST) to discuss its results for the first quarter of fiscal 2024.
The dial-in details for the call are as follows:
About Piramal Pharma Ltd:
Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), offers a portfolio of differentiated products and services through its 17 global development and manufacturing facilities and a global distribution network in more than 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex business of hospital generics; and the India Consumer Healthcare business, which sells over-the-counter products. In addition, one of PPL’s partner companies, Allergan India Private Limited, is a joint venture with AbbVie Inc. and has become one of the market leaders in the area of ophthalmic therapy. In addition, PPL has a minority investment in Yapan Bio Private Limited. In October 2020, PPL received a 20% strategic growth investment from the Carlyle Group.
For more information, visit: www.piramaI.com/pharma I I inker1ln | Facebook and Twitter.
Photo: https://mma.prnewswire.com/media/2169456…Logo: https://mma.prnewswire.com/media/1855206…
View original content: https://www.prnewswire.com/es/comunicados-de-prensa/piramal-pharma-limited-anuncia-resultados-consolidados-para-el-primer-trimestre-del-ano-fiscal-2024-301893576.html
